Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
Top Page
Cogent Biosciences
(NASDAQ:COGT)
35Underperform
Positive Factors
Clinical Trial Results
Cogent presented favorable Part 1 results from the Phase 3 Peak trial, which is evaluating bezuclastinib + sunitinib in 2L GIST.
Market Opportunity
Bezu may be able to capture broader market share in advanced systemic mastocytosis due to its more favorable heme tox profile.
Treatment Efficacy
Bezuclastinib resulted in significant improvements in symptom severity as measured by Cogent's novel patient-reported outcome measurement scale.
Negative Factors
Competitive Landscape
It appears that IDRX-42 yields a greater efficacy profile than bezuclastinib + sunitinib.
Pricing Target
The 12-month price target has been lowered to $14 from the prior $17 per share.
Safety Concerns
Investors will scrutinize the liver toxicity profile of bezuclastinib following the disclosure of 3 total cases of Gr3 AST/ALT elevations in ISM.
Cogent Biosciences (COGT) vs. S&P 500 (SPY)
Market Cap
$659.19M
Dividend YieldN/A
Average Volume (3M)1.27M
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue GrowthN/A
EPS Growth-2.53%
CountryUS
Employees205
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.46
Shares Outstanding113,850,090
10 Day Avg. Volume1,389,419
30 Day Avg. Volume1,271,856
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)930.20
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.67Price Target Upside212.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Cogent Biosciences Business Overview & Revenue Model
Company DescriptionCogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies to treat genetically driven diseases. The company operates primarily in the biopharmaceutical sector and is dedicated to advancing its core product pipeline, which includes experimental therapies for specific genetic mutations linked to rare disorders and cancers. Cogent Biosciences aims to address unmet medical needs through targeted treatment options, leveraging its expertise in genetic and molecular biology.
How the Company Makes MoneyCogent Biosciences makes money primarily through the development and commercialization of its precision therapies. The company generates revenue by advancing its drug candidates through clinical trials, securing regulatory approvals, and eventually launching these products into the market. Revenue streams include potential sales of approved therapies, milestone payments, and royalties from partnerships with larger pharmaceutical companies who may assist in the distribution and marketing of their products. Significant partnerships with other biotech firms and research institutions may also contribute to earnings by sharing resources, expertise, and financial support in the development of their therapies.
Cogent Biosciences Financial Statement Overview
Summary
Cogent Biosciences faces significant financial challenges, with no recent revenue and consistent operating losses. While the company has a strong equity position, its reliance on external financing and negative cash flows highlight financial instability.Income Statement
Cogent Biosciences has experienced declining revenue over the years, with no recorded revenue in recent periods. Despite a high gross profit in earlier years, recent operating losses have been substantial, leading to negative EBIT and net income. The absence of revenue growth and consistent net losses indicate a challenging profitability environment.20
Very Negative
Balance Sheet
The company's balance sheet shows a strong equity position with a high equity ratio, indicating limited financial leverage. However, persistent negative net income has impacted equity growth. Despite a relatively low debt-to-equity ratio, the lack of revenue generation poses a risk to financial stability.35
Negative
Cash Flow
Cogent Biosciences has consistently negative operating and free cash flows, which raises concerns about long-term sustainability. While financing activities have historically supported liquidity, the reliance on external funding and absence of positive cash flow from operations suggest financial vulnerabilities.30
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 7.87M | Gross Profit |
| 0.00 | -3.59M | -5.88M | -147.00K | 7.85M | EBIT |
| -275.94M | -208.13M | -147.84M | -75.55M | -82.20M | EBITDA |
| -275.94M | -205.86M | -134.36M | -75.40M | -34.57M | Net Income Common Stockholders |
| -255.86M | -192.41M | -132.64M | -71.81M | -66.45M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 287.08M | 265.71M | 259.28M | 219.68M | 242.19M | Total Assets |
| 327.90M | 313.44M | 300.81M | 232.09M | 250.92M | Total Debt |
| 17.47M | 18.85M | 19.65M | 3.15M | 5.21M | Net Debt |
| -80.70M | -34.38M | -120.24M | -216.53M | -236.98M | Total Liabilities |
| 71.61M | 55.63M | 45.08M | 17.91M | 16.25M | Stockholders Equity |
| 256.29M | 257.80M | 255.74M | 214.18M | 234.67M |
| Cash Flow | Free Cash Flow | |||
| -207.79M | -156.42M | -125.50M | -60.48M | -35.85M | Operating Cash Flow |
| -207.79M | -153.62M | -118.64M | -58.76M | -35.85M | Investing Cash Flow |
| 38.28M | -97.82M | -124.72M | -1.72M | 8.42M | Financing Cash Flow |
| 214.45M | 163.54M | 163.56M | 37.98M | 232.20M |
Cogent Biosciences Technical Analysis
Negative
5.33
Price Trends
7.73
Negative
8.23
Negative
9.14
Negative
Market Momentum
-0.41
Positive
31.36
Neutral
11.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COGT, the sentiment is Negative. The current price of 5.33 is below the 20-day moving average (MA) of 6.92, below the 50-day MA of 7.73, and below the 200-day MA of 9.14, indicating a bearish trend. The MACD of -0.41 indicates Positive momentum. The RSI at 31.36 is Neutral, neither overbought nor oversold. The STOCH value of 11.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COGT.
Cogent Biosciences Risk Analysis
Cogent Biosciences disclosed 50 risk factors in its most recent earnings report. Cogent Biosciences reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cogent Biosciences Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $682.21M | ― | -37.72% | ― | ― | -3.08% | |
53 Neutral | $762.41M | ― | -913.07% | ― | 31.76% | 24.85% | |
51 Neutral | $716.39M | ― | -25.68% | ― | ― | 68.93% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
47 Neutral | $631.93M | ― | -23.34% | ― | 47.92% | 17.84% | |
41 Neutral | $645.01M | ― | 34.94% | ― | ― | ― | |
35 Underperform | $659.19M | ― | -99.54% | ― | ― | -2.53% |
* Healthcare Sector Average
Performance Comparison
COGT
Cogent Biosciences
5.33
-1.57
-22.75%
PRTA
Prothena
11.32
-11.94
-51.33%
AVXL
Anavex Life Sciences
8.30
3.82
85.27%
EOLS
Evolus
11.39
-2.03
-15.13%
LENZ
LENZ Therapeutics
23.00
2.47
12.03%
BCAX
Bicara Therapeutics Inc.
11.83
-13.58
-53.44%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.